Condition
Cervical Cancer Stage Iv
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Withdrawn1
Terminated1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06998394Phase 2RecruitingPrimary
A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer
NCT03146039Phase 2Withdrawn
Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB
NCT00003525Phase 2TerminatedPrimary
Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva
Showing all 3 trials